COMPUGEN LTD (CGEN) Form 6-K — May 18, 2026
Compugen Ltd. reported Q1 2026 results with a net loss of $7.7 million and revenue of $2.2 million, driven by upfront and milestone payments from its Gilead partnership. The company holds $134.9 million in cash and equivalents, providing a runway into 2029 without debt. Clinical progress remains on track, with the COM701 MAIA-ovarian trial actively enrolling patients across the U.S., Israel, and France.
Key figures
- Revenue
- 2176000
- Total Assets
- 145861000
- Cash Position
- 134900000
- Ga expenses
- 2298000
- Rd expenses
- 6937000
- Cash runway year
- 2029
- Shares outstanding
- 94556230
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.